Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media

被引:77
作者
Genzel, Y.
Olmer, R. M.
Schafer, B.
Reichl, U.
机构
[1] Max Planck Inst Dynam Complex Tech Syst, D-39106 Magdeburg, Germany
[2] Univ Bielefeld, Lehrstuhl Zellkulturtech, D-33615 Bielefeld, Germany
[3] Otto Von Guericke Univ, Lehrstuhl Bioprozesstech, D-39106 Magdeburg, Germany
关键词
wave bioreactor; equine influenza virus; vaccine production; MDCK; microcarrier; serum-free; TCID50; stability; moi; time of infection; amino acids;
D O I
10.1016/j.vaccine.2006.05.023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A process for equine influenza virus vaccine production using a microcarrier system (Cytodex 1) in a 2 L Wave bioreactor is described. Growth of Madin Darby canine kidney (MDCK) cells in serum containing GMEM medium (SC) is compared to growth in serum-free Ex-Cell MDCK medium (SF) without washing steps and medium exchange before infection. Cultivations with microcarrier concentrations of 2 and 4 g/L for both media are shown. Metabolic data from carbon and amino acid metabolism are discussed. Additionally, in roller bottle experiments the influence of multiplicity of infection (moi) and trypsin concentration on the HA value was investigated. Analysis of HA and TCID50 at 37 degrees C showed a stable HA of maximum 2.6 log HA/100 mu L for 2 weeks. Peak TCID50h titers of 10(7.7) viruses/mL were achieved 20 h post infection, but infectivity was below detection limit after 150 h. Cell attachment onto microcarriers under serum-free conditions was improved by Ca2+ addition and by cell harvesting without trypsin using only an EDTA/PBS solution. For the wave cultivation maximum virus titers of 2.3-2.6 log HA units/100 mu L were reached from infection with a moi of 0.05. However, in SF medium pH dropped to less than pH 6.8 which resulted in lower HA titers of 1.7 log HA units/100 mu L. For the higher microcarrier concentration (4 g/L) medium exchange steps (500 mL) were needed for both media. Omission of the washing step and medium exchange before infection in SF medium clearly simplified the influenza production process; however, for higher virus yields a better pH control of the wave bioreactor would be required. Higher cell densities (2.8 x 10(6) cells/mL for 2 g/L microcarrier) and better attachment compared to stirred tank bioreactors showed, that the wave bioreactor is a good alternative to stirred tank processes for expanding production capacities in case of a pandemic. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6074 / 6087
页数:14
相关论文
共 41 条
  • [1] The growth of attenuated influenza vaccine donor strains in continuous cell lines
    Audsley, JM
    Tannock, GA
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2005, 123 (02) : 187 - 193
  • [2] GENETIC-ENGINEERING OF HYBRIDOMA GLUTAMINE-METABOLISM
    BELL, SL
    BEBBINGTON, C
    SCOTT, MF
    WARDELL, JN
    SPIER, RE
    BUSHELL, ME
    SANDERS, PG
    [J]. ENZYME AND MICROBIAL TECHNOLOGY, 1995, 17 (02) : 98 - 106
  • [3] SERUM-FREE CELL-CULTURE
    BJARE, U
    [J]. PHARMACOLOGY & THERAPEUTICS, 1992, 53 (03) : 355 - 374
  • [4] BOCK A, 2005, P 19 ESACT M CELL TE
  • [5] Brands R, 1999, Dev Biol Stand, V98, P93
  • [6] Burteau CC, 2003, IN VITRO CELL DEV-AN, V39, P291
  • [7] Physiology of cultured animal cells
    Doverskog, M
    Ljunggren, J
    Öhman, L
    Häggström, L
    [J]. JOURNAL OF BIOTECHNOLOGY, 1997, 59 (1-2) : 103 - 115
  • [8] Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture
    Genzel, Y
    Fischer, M
    Reichl, U
    [J]. VACCINE, 2006, 24 (16) : 3261 - 3272
  • [9] Substitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells
    Genzel, Y
    Ritter, JB
    König, S
    Alt, R
    Reichl, U
    [J]. BIOTECHNOLOGY PROGRESS, 2005, 21 (01) : 58 - 69
  • [10] Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture
    Genzel, Y
    Behrendt, I
    König, S
    Sann, H
    Reichl, U
    [J]. VACCINE, 2004, 22 (17-18) : 2202 - 2208